Biosimilar Integration: Administration’s Considerations
Release date: October 25, 2019
Expiration date: October 25, 2022
ACPE credit must be claimed by: October 25, 2022
Offered On-Demand only.
This webinar will review the numerous financial, operational, and clinical aspects to consider when implementing biosimilars into oncology care.
- Review the approval and commercialization process of biosimilar medication.
- Examine biosimilars' impact on marketplace trends.
- Review various financial, operational, and clinical considerations for the use of biosimilars.
- Present methods to successfully incorporate biosimilars into oncology workflow.
Philip Schwieterman, PharmD MHA
Philip Schwieterman obtained his bachelors and doctorate of pharmacy degrees from The Ohio State University and his Master of Health Administration from the University of Kentucky. Philip joined UK HealthCare as a Pharmacy Director in 2013 where he has led numerous financial, clinical, and operational initiatives surrounding the growth and oversight of oncology, infusion, specialty and pediatric pharmacy services. He currently serves as the Pharmacy Director for Oncology and Pediatrics.
This activity is intended for Hematology/Oncology pharmacists. This activity has been approved for 1.00 contact hours (.10CEUs) under the ACPE universal activity number # 0465-0000-19-098-H04-P.
HOPA Member ‒ $0
Nonmember ‒ $0
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. A statement of credit will be issued only upon completion of the post-activity evaluation form and post-test. ACPE credit must be claimed by October 25, 2022.
Disclosure of Conflicts of Interest: The Hematology/Oncology Pharmacy Association (HOPA) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by HOPA for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. HOPA is committed to providing its learners with high-quality CE activities and related materials that promote improvements of quality in healthcare and not a specific proprietary business interest of a commercial interest.
Supported by an independent medical education grant from Sandoz Inc., a Novartis Division.